康美药业2025年上半年净利润同比增长7.24%

Core Viewpoint - Kangmei Pharmaceutical reported a revenue of 2.577 billion yuan for the first half of 2025, reflecting a year-on-year growth of 4.17% [2] - The net profit attributable to shareholders reached 16.9014 million yuan, marking a year-on-year increase of 7.24% [2] - The net profit attributable to shareholders, after deducting non-recurring gains and losses, showed a loss of 3.6186 million yuan, an improvement from a loss of 108 million yuan in the same period last year [2] Financial Performance - Revenue for the first half of 2025: 2.577 billion yuan, up 4.17% year-on-year [2] - Net profit attributable to shareholders: 16.9014 million yuan, up 7.24% year-on-year [2] - Net profit after deducting non-recurring items: loss of 3.6186 million yuan, improved from a loss of 108 million yuan in the previous year [2]